Biomedica cuts its losses

Oxford Biomedica, the gene and cell therapy group, has reduced its operating losses to £2.2 million in the first six months of this year, down from £6.9m in the same period of 2016.

Chief executive John Dawson said the group had made significant progress in the period, with the financial flexibility to advance its crucial in-house programmes.